[1] SCARPIGNATO C, GATTA L, ZULLO A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression[J]. BMC Med, 2016, 14(1):179. doi:  10.1186/s12916-016-0718-z
[2] MORI H, SUZUKI H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker[J]. J Neurogastroenterol Motil, 2019, 25(1):6-14. doi:  10.5056/jnm18139
[3] 中华消化杂志编辑委员会, 邹多武, 谢渭芬, 等. 消化性溃疡诊断与治疗共识意见(2022年, 上海)[J]. 中华消化杂志, 2023, 9(3):176-192. doi:  10.3760/cma.j.cn311367-20230115-00022
[4] RAMSAY P T, CARR A. Gastric acid and digestive physiology[J]. Surg Clin North Am, 2011, 91(5):977-982. doi:  10.1016/j.suc.2011.06.010
[5] AIHARA T, NAKAMURA E, AMAGASE K, et al. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future[J]. Pharmacol Ther, 2003, 98(1):109-127. doi:  10.1016/S0163-7258(03)00015-9
[6] NISHIDA H. Discovery of Vonoprazan Fumarate(TAK-438)as a Novel, Potent and Long-Lasting Potassium-Competitive Acid Blocker [M]. Successful Drug Discovery, 2016.
[7] FATOVIĆ-FERENČIĆ S, BANIĆ M. No acid, no ulcer: Dragutin(Carl)Schwarz(1868-1917), the man ahead of his time[J]. Dig Dis, 2011, 29(5):507-510. doi:  10.1159/000334384
[8] MARSHALL B J, WARREN J R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration[J]. Lancet, 1984, 1(8390):1311-1315.
[9] LAM S K. Antacids: the past, the present, and the future[J]. Baillieres Clin Gastroenterol, 1988, 2(3):641-654. doi:  10.1016/S0950-3528(88)80011-3
[10] SCARPIGNATO C, HONGO M, WU J C Y, et al. Pharmacologic treatment of GERD: where we are now, and where are we going?[J]. Ann N Y Acad Sci, 2020, 1482(1):193-212. doi:  10.1111/nyas.14473
[11] SAVARINO E, MARTINUCCI I, FURNARI M, et al. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations[J]. Expert Opin Drug Metab Toxicol, 2016, 12(11):1333-1341. doi:  10.1080/17425255.2016.1214714
[12] RAWLA P, SUNKARA T, OFOSU A, et al. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?[J]. World J Gastrointest Pharmacol Ther, 2018, 9(7):63-68. doi:  10.4292/wjgpt.v9.i7.63
[13] PARSONS M E, KEELING D J. Novel approaches to the pharmacological blockade of gastric acid secretion[J]. Expert Opin Investig Drugs, 2005, 14(4):411-421. doi:  10.1517/13543784.14.4.411
[14] HUNT R H, SCARPIGNATO C. Potassium-competitive acid blockers(P-CABs): are they finally ready for prime time in acid-related disease?[J]. Clin Transl Gastroenterol, 2015, 6(10):e119. doi:  10.1038/ctg.2015.39
[15] ECHIZEN H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations[J]. Clin Pharmacokinet, 2016, 55(4):409-418. doi:  10.1007/s40262-015-0326-7
[16] KANG C. Keverprazan hydrochloride: first approval[J]. Drugs, 2023, 83(7):639-643. doi:  10.1007/s40265-023-01865-w
[17] HORI Y, IMANISHI A, MATSUKAWA J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate(TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases[J]. J Pharmacol Exp Ther, 2010, 335(1):231-238. doi:  10.1124/jpet.110.170274
[18] HE J J, CAO G Y, YU J C, et al. Safety, tolerability and pharmacokinetics of single ascending and multiple oral doses of tegoprazan in healthy Chinese subjects[J]. Clin Drug Investig, 2021, 41(1):89-97. doi:  10.1007/s40261-020-00986-4
[19] OTAKE K, SAKURAI Y, NISHIDA H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate(TAK-438)[J]. Adv Ther, 2016, 33(7):1140-1157. doi:  10.1007/s12325-016-0345-2
[20] OSHIMA T, MIWA H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases[J]. J Neurogastroenterol Motil, 2018, 24(3):334-344. doi:  10.5056/jnm18029
[21] GEIBEL J P. Role of potassium in acid secretion[J]. World J Gastroenterol, 2005, 11(34):5259-5265. doi:  10.3748/wjg.v11.i34.5259
[22] SCOTT D R, MUNSON K B, MARCUS E A, et al. The binding selectivity of vonoprazan(TAK-438)to the gastric H+, K+-ATPase[J]. Aliment Pharmacol Ther, 2015, 42(11-12):1315-1326. doi:  10.1111/apt.13414
[23] LAMBRECHT N, MUNSON K, VAGIN O, et al. Comparison of covalent with reversible inhibitor binding sites of the gastric H, K-ATPase by site-directed mutagenesis[J]. J Biol Chem, 2000, 275(6):4041-4048. doi:  10.1074/jbc.275.6.4041
[24] VAGIN O, MUNSON K, DENEVICH S, et al. Inhibition kinetics of the gastric H, K-ATPase by K-competitive inhibitor SCH28080 as a tool for investigating the luminal ion pathway[J]. Ann N Y Acad Sci, 2003, 986:111-115. doi:  10.1111/j.1749-6632.2003.tb07147.x
[25] SHIN J M, INATOMI N, MUNSON K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate(TAK-438)[J]. J Pharmacol Exp Ther, 2011, 339(2):412-420. doi:  10.1124/jpet.111.185314
[26] HOWDEN C W. Appropriate acid suppression in the treatment of acid-related conditions[J]. Pharmacol Ther, 1994, 63(1):123-134. doi:  10.1016/0163-7258(94)90056-6
[27] BELL N J, BURGET D, HOWDEN C W, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease[J]. Digestion, 1992, 51(Suppl 1):59-67.
[28] TAKAHASHI N, TAKE Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility[J]. J Pharmacol Exp Ther, 2018, 364(2):275-286. doi:  10.1124/jpet.117.244202
[29] LI C Y, SU M, YAN Y Y, et al. KFP-H008 blocks gastric acid secretion through inhibiting H+-K+-ATPase[J]. Eur J Pharmacol, 2017, 810:112-119. doi:  10.1016/j.ejphar.2017.06.020
[30] SAKURAI Y, MORI Y, OKAMOTO H, et al. Acid-inhibitory effects of vonoprazan 20 Mg compared with esomeprazole 20 Mg or rabeprazole 10 Mg in healthy adult male subjects: a randomised open-label cross-over study[J]. Aliment Pharmacol Ther, 2015, 42(6):719-730. doi:  10.1111/apt.13325
[31] JENKINS H, SAKURAI Y, NISHIMURA A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438(vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects[J]. Aliment Pharmacol Ther, 2015, 41(7):636-648. doi:  10.1111/apt.13121
[32] SUNWOO J, JI S C, OH J, et al. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects[J]. Aliment Pharmacol Ther, 2020, 52(11-12):1640-1647. doi:  10.1111/apt.16121
[33] YANG E, KIM S, KIM B, et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole[J]. Br J Clin Pharmacol, 2022, 88(7):3288-3296. doi:  10.1111/bcp.15268
[34] HAN S, CHOI H Y, KIM Y H, et al. Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: a randomized crossover study[J]. Gut Liver, 2023, 17(1):92-99. doi:  10.5009/gnl220050
[35] HAN S, CHOI H Y, KIM Y H, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan(CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects[J]. Aliment Pharmacol Ther, 2019, 50(7):751-759. doi:  10.1111/apt.15438
[36] MULFORD D J, LEIFKE E, HIBBERD M, et al. The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan[J]. Clin Pharmacol Drug Dev, 2022, 11(2):278-284. doi:  10.1002/cpdd.1009
[37] HAN S, CHOI H Y, KIM Y H, et al. Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan[J]. Clin Ther, 2021, 43(8):1371-1380. doi:  10.1016/j.clinthera.2021.06.007
[38] YOON D Y, SUNWOO J, SHIN N, et al. Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers[J]. Clin Transl Sci, 2021, 14(3):934-941. doi:  10.1111/cts.12958
[39] ZHOU S, XIE L, ZHOU C, et al. Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects[J]. Eur J Pharm Sci, 2023, 190:106578. doi:  10.1016/j.ejps.2023.106578
[40] YAMASAKI H, KAWAGUCHI N, NONAKA M, et al. In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker[J]. Xenobiotica, 2017, 47(12):1027-1034. doi:  10.1080/00498254.2016.1203505
[41] YONEYAMA T, TESHIMA K, JINNO F, et al. A validated simultaneous quantification method for vonoprazan(TAK-438F)and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry[J]. J Chromatogr B, 2016, 1015-1016:42-49. doi:  10.1016/j.jchromb.2016.01.051
[42] JEONG H C, KIM M G, WEI Z D, et al. Integration of a physiologically based pharmacokinetic and pharmacodynamic model for tegoprazan and its metabolite: application for predicting food effect and intragastric pH alterations[J]. Pharmaceutics, 2022, 14(6):1298. doi:  10.3390/pharmaceutics14061298
[43] NGO L T, LEE J, YUN H Y, et al. Development of a physiologically based pharmacokinetic model for tegoprazan: application for the prediction of drug-drug interactions with CYP3A4 perpetrators[J]. Pharmaceutics, 2023, 15(1):182. doi:  10.3390/pharmaceutics15010182
[44] SAKURAI Y, NISHIMURA A, KENNEDY G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438(vonoprazan)doses in healthy male Japanese/non-japanese subjects[J]. Clin Transl Gastroenterol, 2015, 6(6):e94. doi:  10.1038/ctg.2015.18
[45] WANG Y R, WANG C X, WANG S H, et al. Cytochrome P450-based drug-drug interactions of vonoprazan in vitro and in vivo[J]. Front Pharmacol, 2020, 11:53. doi:  10.3389/fphar.2020.00053
[46] HWANG S, KO J W, LEE H, et al. Co-administration of vonoprazan, not tegoprazan, affects the pharmacokinetics of atorvastatin in healthy male subjects[J]. Front Pharmacol, 2021, 12:754849. doi:  10.3389/fphar.2021.754849
[47] YOON D Y, LEE S, JANG I J, et al. Prediction of drug-drug interaction potential of tegoprazan using physiologically based pharmacokinetic modeling and simulation[J]. Pharmaceutics, 2021, 13(9):1489. doi:  10.3390/pharmaceutics13091489
[48] KAGAMI T, YAMADE M, SUZUKI T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype[J]. Clin Pharmacol Ther, 2018, 103(5):906-913. doi:  10.1002/cpt.863
[49] NISHIHARA M, YAMASAKI H, CZERNIAK R, et al. In vitro assessment of potential for CYP-inhibition-based drug-drug interaction between vonoprazan and clopidogrel[J]. Eur J Drug Metab Pharmacokinet, 2019, 44(2):217-227. doi:  10.1007/s13318-018-0521-7
[50] NISHIHARA M. Inhibitory effect of vonoprazan on the metabolism of[14C]prasugrel in human liver microsomes[J]. Eur J Drug Metab Pharmacokinet, 2019, 44(5):713-717. doi:  10.1007/s13318-019-00554-y
[51] YANG E, JI S C, JANG I J, et al. Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole[J]. Clin Pharmacokinet, 2023, 62(4):599-608. doi:  10.1007/s40262-023-01228-4
[52] SAKURAI Y, SHIINO M, OKAMOTO H, et al. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study[J]. Adv Ther, 2016, 33(9):1519-1535. doi:  10.1007/s12325-016-0374-x
[53] GHIM J L, CHIN M C, JUNG J, et al. Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects[J]. J Clin Pharmacol, 2021, 61(7):913-922. doi:  10.1002/jcph.1805
[54] JEON J Y, KIM S Y, MOON S J, et al. Pharmacokinetic interactions between tegoprazan and metronidazole/tetracycline/bismuth and safety assessment in healthy Korean male subjects[J]. Clin Ther, 2021, 43(4):722-734. doi:  10.1016/j.clinthera.2021.01.026
[55] MOON S J, SHIN N, KANG M, et al. Pharmacokinetic interactions between tegoprazan and naproxen, aceclofenac, and celecoxib in healthy Korean male subjects[J]. Clin Ther, 2022, 44(7): 930-944. e1.